News
ESMO: Amgen reveals Lumakras data as rival looms in rear-vie...
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in
